Alex H. Ramos

Intarcia Therapeutics (United States) — United States

Medicine · Health Sciences

25h-index33.4kcitations85works2.02yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Esophageal Cancer Research and Treatment(19), Cancer Genomics and Diagnostics(17), Gastric Cancer Management and Outcomes(16), Lung Cancer Treatments and Mutations(13), Cancer-related gene regulation(10)

Publications84 total

Functional and structural characterization of a combination of pan-sarbecovirus antibodies with potent antiviral activity

2 cited

2025· 2 citedOpen Access

Supplementary Figures 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Data from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Supplementary Figure Legends 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Supplementary Figure Legends 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Data from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Interview with Dr. Meyerson from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Interview with Dr. Meyerson from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Supplementary Figures 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2023Open Access

Supplementary Figure 14 from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

Data from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

Supplementary Note 3 from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

Supplementary Tables 1-6 from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

Supplementary Note 2 from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

Supplementary Note 1 from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

Data from Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma

2023Open Access

Supplementary Note 1 from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

Supplementary Legends for Figures 1-14, and Tables 1-6 from Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

2023Open Access

page 1 of 5Next →

Frequent Co-authors

Matthew Meyerson(42), Michael S. Lawrence(25), Gordon Saksena(24), Gad Getz(22), Kristian Cibulskis(21), Andrey Sivachenko(20), Robert C. Onofrio(20), Adam J. Bass(18), Daniel Auclair(17), Wendy Winckler(17), Stacey Gabriel(17), David G. Beer(17), Scott L. Carter(15), Carrie Sougnez(15), Douglas Voet(15), Levi A. Garraway(15), Rameen Beroukhim(15), Jordi Barretina(15), Sylvan C. Baca(13), Todd R. Golub(13)